Literature DB >> 22762140

HCV burden of infection in Egypt: results from a nationwide survey.

J Guerra1, M Garenne, M K Mohamed, A Fontanet.   

Abstract

Egypt is the country with the largest hepatitis C virus (HCV) epidemic in the world. In 2008, a Demographic Health Survey (DHS) was carried out in Egypt, providing for the first time a unique opportunity for HCV antibody testing on a nationwide representative sample of individuals. Consenting individuals answered a questionnaire on socio-demographic characteristics and iatrogenic exposures, before providing a blood sample for HCV antibody testing by enzyme-linked immunosorbent assay. Factors independently associated with HCV infection were examined through multivariate logistic regression models. Of 12 780 eligible subjects aged 15-59 years, 11 126 (87.1%) agreed to participate and provided a blood sample. HCV antibody prevalence nationwide was 14.7% (95% CI 13.9-15.5%) in this age group. HCV antibody prevalence gradually increased with age, reaching, in the 50-59 years age group, 46.3% and 30.8% in males and females, respectively. It was higher in males compared to females (17.4% versus 12.2%, respectively, P < 0.001), and in rural compared to urban areas (18.3% versus 10.3%, respectively, P < 0.001). In multivariate analysis, age, male sex, poverty, past history of intravenous anti-schistosomiasis treatment, blood transfusion, and living outside of the Frontier Governorates were all significantly associated with an increased risk of HCV infection. In addition, in urban areas, lack of education and being circumcised for females were associated with an increased risk of HCV infection. This study confirmed on a nationwide representative sample the very high HCV antibody prevalence in Egypt. It stresses the urgent need for strengthening prevention efforts, and bringing down the costs of antiviral drugs for countries like Egypt, where the people in the most precarious situations are also those most likely to be infected by the virus.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762140     DOI: 10.1111/j.1365-2893.2011.01576.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  70 in total

1.  Wide Sexual Dimorphism of Hepatocellular Carcinoma Presentation in Algeria.

Authors:  Yazid Chikhi; Salima Cheraitia; Rachid Ould Gougam; Fadila Lounes; Chahrazed Zemmouchi; Nassila Belal; Maroua Bendaoud; Sonia Ait Younes; Aicha Bensalem; Saadi Berkane; Hocine Asselah; Pascal Pineau; Mustapha Lahcene
Journal:  Gastrointest Tumors       Date:  2019-08-30

2.  Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates.

Authors:  Ashraf Elbahrawy; Ahmed Elwassief; Abdallah Mahmoud Abdallah; Arafat Kasem; Sadek Mostafa; Khaled Makboul; Mohamed Salah Ali; Ahmed Alashker; Ahmed Maher Eliwa; Hossam Shahbah; Mohamed Abdellah Othman; Mohamed Hanafy Morsy; Mohamed Ali Abdelbaseer; Hafez Abdelhafeez
Journal:  J Transl Int Med       Date:  2017-09-30

3.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

4.  Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.

Authors:  Susanne Knapp; Zainab Zakaria; Mohamed Hashem; Hassan Zaghla; Salim I Khakoo; Imam Waked; Mark Thursz; Sayed F Abdelwahab
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

5.  Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients.

Authors:  Walaa R Allam; Ahmed Barakat; Zainab Zakaria; Gehan Galal; Tamer S Abdel-Ghafar; Mohamed El-Tabbakh; Nabiel Mikhail; Imam Waked; Sayed F Abdelwahab
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

6.  Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.

Authors:  Ahmed Megahed; Nanees Salem; Abeer Fathy; Tarik Barakat; Mona Abd El Latif Alsayed; Suzy Abd El Mabood; Khaled R Zalata; Ahmed F Abdalla
Journal:  World J Pediatr       Date:  2017-01-27       Impact factor: 2.764

Review 7.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

8.  Diagnostic non-invasive model of large risky esophageal varices in cirrhotic hepatitis C virus patients.

Authors:  Hatem Elalfy; Walid Elsherbiny; Ashraf Abdel Rahman; Dina Elhammady; Shaker Wagih Shaltout; Ayman Z Elsamanoudy; Bassem El Deek
Journal:  World J Hepatol       Date:  2016-08-28

9.  Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: an Egyptian study.

Authors:  Hanan Fouad; Maissa Saeed El Raziky; Rasha Ahmed Abdel Aziz; Dina Sabry; Ghada Mahmoud Abdel Aziz; Manal Ewais; Ahmed Reda Sayed
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 10.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.